Background: The purpose of the phase I dose-escalation study was to evaluate the maximum tolerated dose (MTD) of BIBF 1120, an oral triple angiokinase inhibitor of vascular endothelial growth factor, platelet derived growth factor and fibroblast growth factor receptors, combined with paclitaxel and carboplatin. 
introduction
Even after optimal treatment, only a minority of patients with stage III or IV ovarian cancer will be alive 5 years after diagnosis [1] . This high mortality rate has been largely associated with intrinsic and acquired resistance to currently available cytotoxic agents. Novel treatment strategies are therefore required.
Angiogenesis is thought to play a central role in the pathogenesis and clinical behavior of ovarian cancer, and markers of increased angiogenesis are correlated with poor prognosis [2] . The vascular endothelial growth factor (VEGF) is a key mediator regulating angiogenesis [3, 4] and is expressed in the majority of tumor specimens from patients with ovarian cancer [5] . Early clinical data with the anti-VEGF agent bevacizumab have demonstrated that patients with gynecological cancers can benefit from antiangiogenic compounds [6] [7] [8] .
BIBF 1120 is an orally available triple angiokinase inhibitor that simultaneously and potently inhibits vascular endothelial growth factor receptors, platelet derived growth factor receptors and fibroblast growth factor receptors [9] . In vivo studies demonstrated that BIBF 1120 significantly inhibits tumor growth in established xenografts in mice [9] . In a phase I clinical study in patients with advanced solid tumors, BIBF 1120 had a favorable safety profile as twice-daily (b.i.d.) dosing up to the maximum tolerated dose (MTD) of 250 mg b.i.d. [10] .
The aim of this study was to determine the MTD of BIBF 1120 b.i.d. in combination with standard-dose paclitaxel and carboplatin in patients with gynecological cancer. In addition, the safety, tolerability, clinical activity, pharmacokinetics (PK) and drug-drug interactions of BIBF 1120 in this dosing regimen were explored.
patients and methods

study population
Patients with a histologically confirmed diagnosis of an advanced or recurrent gynecological malignancy (epithelial ovarian cancer, endometrial original article [12] in which the doses of standard chemotherapy (paclitaxel/ carboplatin) were held fixed and only BIBF 1120 was escalated. The following dose levels of BIBF 1120 were planned: 100, 150, 200 and 250 mg b.i.d. The MTD was defined as the dose at which <33% of patients experienced a doselimiting toxicity (DLT) in the first treatment period. Once the highest dose or MTD was reached, this dose cohort was expanded to ‡12 assessable patients.
Patients were ineligible for re-treatment if there was confirmed evidence of disease progression or the patient had not recovered from a DLT 14 days after onset. Patients who had not progressed after six cycles of combination therapy could continue with BIBF 1120 monotherapy for up to four 28-day courses.
safety and tolerability assessments
The incidence and intensity of adverse events (AEs) according to common terminology criteria for adverse events (CTCAE) version 3.0 [13] and standard laboratory tests were evaluated throughout the trial. DLT criteria were as follows: gastrointestinal toxicity (nausea, vomiting, diarrhea, abdominal pain) or hypertension CTCAE grade ‡3 despite optimal supportive care/intervention; non-hematological toxicity CTCAE grade 3/4 except gamma-glutamyl transpeptidase (GGT) elevation; CTCAE grade 4 neutropenia that was uncomplicated for >7 days; neutropenia CTCAE grade 3/4 of any duration associated with fever >38.3°C; CTCAE grade 4 thrombocytopenia or CTCAE grade 3 thrombocytopenia associated with bleeding requiring transfusion; inability to resume BIBF 1120 dosing within 14 days of stopping due to treatment-related toxicity. All DLT events that occurred after the initial treatment period were classified as significant AEs.
PK sampling
Six milliliter of venous blood was collected at prespecified time points for the determination of BIBF 1120, paclitaxel and carboplatin PK profiles (supplemental data, available at Annals of Oncology online). Analysis was carried out according to prespecified procedures (supplemental data, available at Annals of Oncology online).
other outcome measures
Efficacy was monitored by objective tumor response, time to tumor progression and assessment of cancer antigen (CA)-125 [14] . RECIST criteria [15] were used. Patients were assessable for CA-125 response if they had ovarian carcinoma, one or more pretreatment value >35 U/ml with the exception of one local laboratory with the upper limit of normal of 65 U/l and more than two CA-125 values available after first BIBF 1120 administration. Patients were deemed responders if, both at any time after baseline and ‡28 days after baseline, CA-125 decreased by ‡50%, and if at ‡28 days after this first observation of CA-125 response, the reduction by ‡50% was maintained.
results
A total of 23 patients were enrolled; 22 met eligibility criteria and were treated with BIBF 1120. Table 1 details the baseline patient demographic characteristics. 
ECOG, Eastern Cooperative Oncology Group. One exception was a patient with advanced uterine sarcoma, who was first changed to carboplatin AUC 4 minÁmg/ml in the second cycle due to thrombocytopenia and then to weekly paclitaxel administration without carboplatin after starting treatment cycle 4 due to thrombocytopenia. BIBF 1120 was continued. One patient was given cisplatin instead of carboplatin following an allergic reaction to the latter. During the first treatment period, three patients experienced DLTs: both patients from the 250-mg dose cohort reported elevated aspartate aminotransferase (AST; CTCAE grade 3, n = 1; CTCAE grade 4, n = 1) and alanine aminotransferase (ALT; both CTCAE grade 3) levels; one patient from the 200-mg dose cohort experienced diarrhea (CTCAE grade 3). Hence, the MTD for b.i.d. dosing of BIBF 1120 in combination with paclitaxel and carboplatin was defined as 200 mg BIBF 1120 b.i.d.; a total of 13 patients were evaluated at the MTD.
Sixteen of 22 patients received all six planned cycles of combination therapy and went on to receive BIBF 1120 monotherapy. Six patients discontinued combination therapy earlier, most frequently due to AEs (n = 5), with one patient withdrawing consent.
Over the entire study, including both combination and monotherapy phases, nine patients reported DLTs. In addition to the three patients who experienced DLTs in treatment period 1 as outlined above, there were four reports of DLTs in treatment period 2 (increased AST and ALT, n = 1; neutropenia, n = 1; thrombocytopenia, n = 2). There was one reported DLT in treatment period 3 (febrile neutropenia) and one in treatment period 8 during BIBF 1120 monotherapy (increased ALT).
Serious adverse events (SAEs), all requiring hospitalization, were reported for seven (32%) patients over the entire study. Treatment-related SAEs occurred exclusively in the 200-mg BIBF 1120 b.i.d. dose cohort and were as follows: diarrhea and concomitant vomiting (n = 1); diarrhea and thrombocytopenia (n = 1) and leucopenia, neutropenia, lung infiltration and pyrexia (n = 1). SAEs not related to drug treatment were as follows: ascites and dyspnea (n = 1), subileus (n = 1), fluid in uterus and hydrometra (n = 1) and breast cancer (n = 1). Nine patients (41%) discontinued treatment due to AEs, including one patient during the first course of treatment. This patient had grade 3 diarrhea which was not treated according to the recommendations of the protocol. Those that were considered to be BIBF 1120 related, as judged by the investigator, were serious diarrhea and concomitant serious vomiting (n = 1), diarrhea (n = 2) and thrombocytopenia (n = 2). The other reasons were depression (n = 1) in a patient with history of depression, disease progression (n = 1) and subileus (n = 1). In addition, one patient had increased CA-125 levels, indicating disease progression. This was reported as an AE and resulted in discontinuation. There were no deaths reported during the study.
The most frequently reported AEs over the entire study were gastrointestinal disorders (n = 22, 100%), mostly of grade 1 and 2. The most common AEs were alopecia (91%), diarrhea (86%), fatigue (64%), myalgia (55%), nausea (59%) and vomiting (55%). All other individual AEs were reported by less than one-third of all patients. The incidence of drug-related AEs, by highest CTCAE grade, occurring in the MTD cohort (200 mg BIBF 1120 b.i.d.) and in the 250-mg BIBF 1120 b.i.d. dose cohort, over the entire study is summarized in Table 2 .
The incidence and pattern of AEs reported during the combination therapy phase was similar to the cumulative incidence and pattern of AEs for the entire study. The AE profile during the monotherapy phase differed from the AE profile original article Annals of Oncology during the entire study; the incidence of gastrointestinal disorders was lower (56%) than during the entire study and the incidences of skin and s.c. tissue disorder and musculoskeletal and connective tissue disorders were markedly decreased compared with combination therapy, mainly due to the absence of any cases of alopecia or myalgia on BIBF 1120 monotherapy. With the exception of liver enzymes, there were no clinically meaningful differences between dose groups with respect to median change from baseline in safety laboratory parameters. There were incidences of elevated AST, ALT and GGT, particularly in the 250-mg BIBF 1120 b.i.d. dose cohort, in which two patients had CTCAE grade 3 or 4 elevations of AST and/or ALT values during treatment period 1 that qualified as DLT events. These, and indeed all deteriorations in safety laboratory parameters, were reversible. During the entire study, one incidence of hypertension (grade 2) occurred in the 200-mg b.i.d. dose tier.
pharmacokinetics
The PK parameters of paclitaxel and carboplatin are shown in Table 3 
discussion
The MTD of BIBF 1120 in this combination regimen was determined to be 200 mg b.i.d., which is comparable to that observed in another phase I trial of BIBF 1120 combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer [16] . No dose reduction of paclitaxel or carboplatin due to continuous administration of BIBF 1120 was necessary. The combination of BIBF 1120 b.i.d. with paclitaxel and carboplatin had an acceptable safety profile. The majority of AEs were of CTCAE grade 1 or 2 and the most frequently reported AEs were gastrointestinal disorders, primarily diarrhea, nausea and vomiting. This AE profile is consistent with those observed with other angiogenesis inhibitors [17] [18] [19] [20] . In contrast to other angiogenesis inhibitors, however [17] [18] [19] , we did not observe any significant incidence of hypertension in this study. Five patients reported grade 3 ALT elevations, two patients had grade 3 AST elevations and there was one incidence of grade 4 AST elevation. All these elevations were found in the higher dose groups of BIBF 1120 (200 and 250 mg b.i.d.) but resolved during the study and were reversible.
A 20-day continuous administration of BIBF 1120 in combination with paclitaxel and carboplatin showed objective antitumor activity in this mixed group of gynecological patients. According to RECIST, one patient had a CR, four patients had a PR and two patients had an SD as their best overall response. All ten patients that were assessable for CA-125 response were responders, and 9 of 10 remained so until the end of the trial.
The addition of 200 mg b.i.d. BIBF 1120 appeared to have no clinically significant effect on the PK parameters of paclitaxel or carboplatin. When comparing geometric mean (gMean) AUC 0-N and C max values of paclitaxel before and after BIBF 1120 treatment, an increase of 20%-25% was seen. This increase was not considered clinically relevant as no systematic increases were seen in either of the parameters between treatment periods. With respect to carboplatin, after BIBF 1120 administration, gMean C max values were bioequivalent, although a 25% increase in gMean AUC 0-N was observed. Again, due to the apparent lack of systematic increase between treatment periods, this was deemed to be clinically irrelevant. Although this study was not sized formally to determine drugdrug interactions, the gMean ratios and 90% confidence intervals of AUC 0-N and C max between treatment period 1 (absence of BIBF 1120) and treatment period 2 (presence of BIBF 1120) for each drug do not fall entirely within or out of the 0.8-1.25 range for bioequivalence. However, given the high background exposure variability of these drugs [21] [22] [23] , these data indicate that if any interaction (undetectable as statistically significant) of BIBF 1120 treatment on the PK of a single dose of 175 mg/m 2 paclitaxel or on a single dose of AUC 5 minÁmg/ ml carboplatin were to exist, it is unlikely to be clinically significant.
The single-dose and steady-state PK parameters that were observed in this study of BIBF 1120, administered in combination with paclitaxel and carboplatin, are comparable to those seen with single-agent dosing [24] . This indicates that there were no unfavorable drug-drug interactions of paclitaxel and carboplatin on the PK of BIBF 1120.
In conclusion, the MTD of BIBF 1120 was 200 mg b.i.d. in a 20-day continuous dosing regimen with standard-dose paclitaxel (175 mg/m 2 ) and carboplatin (AUC 5 minÁmg/ml) in patients with advanced gynecological malignancies. This treatment regimen was seen to have an acceptable safety profile, consisting primarily of gastrointestinal disorders. There was no effect of any clinically relevant drug-drug interaction of BIBF 1120, on the PK of either carboplatin or paclitaxel, and neither drug appreciably altered the PK of BIBF 1120. The addition of the novel triple angiokinase inhibitor BIBF 1120 does not impair the application of standard paclitaxel/carboplatin, is tolerable and offers an orally available new mode of antitumor treatment. More advanced phase studies of BIBF 1120 in patients with gynecological malignancies are warranted. The Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe (AGO study group) is currently planning a randomized evaluation of BIBF 1120 concomitant with platinum-paclitaxel and as maintenance therapy in first-line treatment of advanced ovarian cancer.
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